60 Degrees Pharmaceuticals Licenses FSU Technology for Botanical Supplement
Exclusive patent deal for Australian Chestnut Extract positions company to pursue FDA pathway for over-the-counter formulation.
60 Degrees Pharmaceuticals has secured an exclusive patent license from Florida State University for the non-prescription development and commercialization of Australian Chestnut Extract as a botanical supplement.
The agreement grants 60 Degrees Pharmaceuticals rights to FSU's proprietary technology for producing the extract. The company plans to engage with the FDA before refiling its Natural and Non-prescription Drug Information submission, commonly known as an NDIN.
The move signals the company's strategy to move the extract through the regulatory pathway governing over-the-counter botanical supplements. An NDIN filing allows manufacturers to seek FDA review and approval for non-prescription drugs or botanical ingredients prior to market entry.
By licensing established technology from an academic institution, 60 Degrees Pharmaceuticals aims to accelerate development timelines and reduce costs associated with in-house formulation research. The exclusive terms prevent competing manufacturers from accessing FSU's extraction method during the agreement period.
The company's decision to pursue FDA discussions before refiling suggests it is seeking guidance on regulatory requirements and data submissions needed for approval. This approach allows manufacturers to clarify expectations with regulators and adjust their filings accordingly before formal resubmission.
Australian Chestnut Extract has emerged as a point of commercial interest within the botanical supplement sector, though the specific health claims or therapeutic applications the company intends to pursue remain unspecified. The licensing arrangement represents a capital-efficient route to intellectual property compared with independent development.